According to a Securities and Exchange Commission (SEC) filing dated February 24, 2026, River Road Asset Management, LLC established a new position in AptarGroup (NYSE:ATR) by acquiring 917,670 shares. The estimated value of this trade is $111.92 million. The quarter-end value of the stake also totaled $111.92 million, reflecting the full impact of the new position.
This was a new position for River Road, representing 1.23% of 13F reportable assets under management as of December 31, 2025.
Top five holdings after the filing:
-
NYSE:BJ: $306.44 million (3.4% of AUM)
-
NYSE:WTM: $251.19 million (2.8% of AUM)
-
NYSE:LAD: $246.81 million (2.7% of AUM)
-
NYSE:BRK.B: $225.15 million (2.5% of AUM)
-
NASDAQ:MGRC: $223.62 million (2.5% of AUM)
As of February 28, 2026, AptarGroup shares were trading at $143.71, down 1.32% over the past year and underperforming the S&P 500 by 18.68 percentage points.
|
Metric |
Value |
|---|---|
|
Revenue (TTM) |
$3.78 billion |
|
Net Income (TTM) |
$393 million |
|
Dividend Yield |
1.29% |
|
Price (as of market close Feb. 27, 2026) |
$143.71 |
AptarGroup offers dispensing, sealing, and material science solutions for the beauty, personal care, home care, pharmaceutical, consumer health care, injectable, and food and beverage markets.
The company generates revenue through the sale of proprietary pumps, closures, aerosol valves, elastomeric packaging, and active material science solutions, with operations organized into Pharma, Beauty and Home, and Food and Beverage segments.
It serves global customers in the pharmaceutical, consumer packaged goods, and food and beverage sectors, distributing products through direct sales, independent representatives, and distributors across Asia, Europe, Latin America, and North America.
In the company’s fourth-quarter report, leadership noted that sales increased by 14%, with all core segments delivering growth in 2025. Last year also marked the 32nd consecutive year of dividend increases, with a current dividend yield of 1.29%, as of this writing.
AptarGroup focuses on sustainability, with a commitment to sourcing 100% of its electricity needs from renewable resources by 2030. The company also adheres to emissions reduction goals, aligning with the Science Based Targets Initiative. For investors seeking stocks focused on reducing environmental impact, this could be a factor to consider.
Going forward, leadership expects the pharma segment to deliver strong growth, particularly within injectables, consumer healthcare solutions, and systemic nasal drug delivery. Its beauty and closures segments are also expected to remain steady in 2026.
